Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Drug Industry Situation Uncertain But Hopeful

Drug Industry Situation Uncertain But Hopeful "Much of the future impact of the regulations on research will depend on just how wisely the Food and Drug Administration administers them." James D. Gallagher, MD, director of Medical Research at Lederle Laboratories, told the American College of Neuropsychopharmacology in Washington, DC, Jan 16. "We are currently in a period of transition," Gallagher said, and although it is an uncertain situation, it is a hopeful one. In order to get at the real problems facing the pharmaceutical industry and the research community, we must accept certain facts and realize that some of them for the moment appear immutable." First, recent regulatory events have made it clear that government, industry, and the community of clinical investigators are in business together. "At least for a time it appeared to us that there was an unwillingness of government and the investigator to recognize each other's presence in this problem. In the http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png JAMA American Medical Association

Drug Industry Situation Uncertain But Hopeful

JAMA , Volume 187 (11) – Mar 14, 1964

Drug Industry Situation Uncertain But Hopeful

Abstract


"Much of the future impact of the regulations on research will depend on just how wisely the Food and Drug Administration administers them." James D. Gallagher, MD, director of Medical Research at Lederle Laboratories, told the American College of Neuropsychopharmacology in Washington, DC, Jan 16.
"We are currently in a period of transition," Gallagher said, and although it is an uncertain situation, it is a hopeful one. In order to get at the real...
Loading next page...
 
/lp/american-medical-association/drug-industry-situation-uncertain-but-hopeful-WhbghK0phO
Publisher
American Medical Association
Copyright
Copyright © 1964 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
ISSN
0098-7484
eISSN
1538-3598
DOI
10.1001/jama.1964.03060240109061
Publisher site
See Article on Publisher Site

Abstract

"Much of the future impact of the regulations on research will depend on just how wisely the Food and Drug Administration administers them." James D. Gallagher, MD, director of Medical Research at Lederle Laboratories, told the American College of Neuropsychopharmacology in Washington, DC, Jan 16. "We are currently in a period of transition," Gallagher said, and although it is an uncertain situation, it is a hopeful one. In order to get at the real problems facing the pharmaceutical industry and the research community, we must accept certain facts and realize that some of them for the moment appear immutable." First, recent regulatory events have made it clear that government, industry, and the community of clinical investigators are in business together. "At least for a time it appeared to us that there was an unwillingness of government and the investigator to recognize each other's presence in this problem. In the

Journal

JAMAAmerican Medical Association

Published: Mar 14, 1964

There are no references for this article.